Topiramate as add-on treatment for patients with bipolar mania

Bipolar Disorders

Volumn 1, Issue 1, 1999, Pages 42-53

  Chengappa, K N Roy ^a,b,c   Rathore, Dilip ^b   Levine, Joseph ^a,c   Atzert, Rebecca ^a,b,c   Solai, Lalith ^a   Parepally, Haranath ^a,b   Levin, Harry ^a   Moffa, Nicolas ^a   Delaney, Joyce ^a,b   Brar, Jaspreet S ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Mayview State Hospital   (United States)

^c Stanley Ctr Innov Treatm B   (United States)

Author keywords

Anticonvulsant; Bipolar disorder; Depression; Mania; Psychotic disorders; Topiramate; Weight loss

Indexed keywords

4 AMINOBUTYRIC ACID; ACETIC ACID DERIVATIVE; AMINE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; DRUG DERIVATIVE; FRUCTOSE; GABAPENTIN; LITHIUM; TOPIRAMATE; TRANQUILIZER; VALPROIC ACID;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; BODY MASS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ACETIC ACIDS; ADULT; AGED; AMINES; ANTICONVULSANTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; BODY MASS INDEX; CARBAMAZEPINE; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LITHIUM; MALE; MIDDLE AGED; TREATMENT OUTCOME; VALPROIC ACID;

EID: 0033188340     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5618.1999.10111.x     Document Type: Article

References (35)

1. Takezaki H, Hanaoka M. The use of carbamazepine (Tegretol) in the control of manic-depressive psychoses and other manic, depressive states. Clin Psychiatry 1971; 13: 173-182.
2. Okuma T, Kishimoto A, Inoue K, Matsumoto H, Ogura A, Matsushita T, Naklao T, Ogura C. Anti-manic and prophylactic effects of carbamazepine on manic-depressive psychosis. Folia Psychiatr Neurol Jpn 1973; 27: 283-297.
3. Ballenger JC, Post RM. Therapeutic effects of carbamazepine in affective illness: preliminary report. Commun Psychopharmacol 1978; 2: 159-175.
4. Dalby MA. Antiepileptic and psychotropic effect of carbamazepine (Tegretol) in the treatment of psychomotor epilepsy. Epilepsia 1971; 12: 325-334.
5. Post RM, Uhde TW. Treatment of mood disorders with antiepileptic medications: clinical and theoretical implications. Epilepsia 1983; 24 (Suppl 2): S97-S108.
6. Wauquier A, Zhou S. Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res 1996; 24: 73-77.
7. Shank RP, Gardocki JF, Vaught JL, Davis CB, Schupsky JJ, Raffa RB, Dodgson SJ, Nortey SO, Maryanoff BE. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994; 35: 450-460.
8. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997; 28: 167-179.
9. Coulter DA, Sombati S, DeLorenzo RJ. Selective effects of topirmate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia 1993; 34 (Suppl 2): 123.
10. Coulter DA, Sombati S, DeLorenzo RJ. Topiramate effects on excitatory amino-acid-mediated responses in cultured hippocampal neurons: selective blockade of kainate currents. Epilepsia 1995; (Suppl 3): S40.
11. Young RC, Biggs JT, Zeigler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
12. Calabrese JR, Shelton MD, Keck PE Jr, McElroy SL, Werkner JE. Pilot study of topiramate in severe treatment-refractory mania. Abstract NR 202. 151st Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 30-June 4, 1998.
13. Calabrese JR, Shelton MD, Keck PE Jr, McElroy SL. Topiramate in severe treatment-refractory mania. Poster presented at XXIst Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP), Glasgow, Scotland, July 1998.
14. Marcotte D, Gullick E. Use of topiramate, a new antiepileptic drug, as a mood stabilizer. Poster presented at XXIst Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP), Glasgow, Scotland, July 1998.
15. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition. Washington, DC, American Psychiatric Association, 1994.
16. Spearing MK, Post PM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatric Res 1997; 73: 159-171.
17. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
18. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. National Institutes of Health. National Heart, Lung, and Blood Institute, Information Center, PO Box 30105, MD 20824-0105, USA. June 1998.
19. McElroy SL, Kmetz GF, Keck PE Jr. A pilot trial of adjunctive topiramate in the treatment of bipolar disorder. Poster presented at XXIst Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP), Glasgow, Scotland, July 1998.
20. Hussein MZ, Chaudhry ZA. Treatment of bipolar depression with topiramate: a new anticonvulsant drug. Abstract Book NRP26. 48th Annual Meeting of the Canadian Psychiatric Association, Halifax, Nova Scotia, Canada, September 15-18, 1998, p. 44.
21. Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, Karim RM. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996; 46: 1684-1690.
22. Privitera M, Fincham R, Penry J, Reife R, Kramer L, Pledger G, Karim R. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Neurology 1996; 46: 1678-1683.
23. Ben Menachem E, Henriksen O, Dam M, Schmidt D. Double blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996; 37: 539-543.
24. Tassinari CA, Mechelucci R, Chauvel P, Chodiewicz J, Shorvon S, Henriksen O, Dam M, Reife R, Pledger G, Karim R. Double blind placebo controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996; 37: 763-768.
25. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996; 313: 1169-1174.
26. Product information reference source - Topamax® (topiramate) tablets. Department of Medical Information, Ortho-McNeil Pharmaceutical, January 1997.
27. Shorvon SD. Safety of topiramate: adverse effects and relationships to dosing. Epilepsia 1996; 37 (Suppl 2): S18-S22.
28. Rosenfeld WE, PADS Investigator Group. Weight loss associated with topiramate, a new antiepileptic drug with potential psychoactive effects. Poster presented at XXIst Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP), Glasgow, Scotland, July 1998.
29. Topamax® (topiramate) tablets. Package insert and prescribing information. McNeil Pharmaceutical, McNeillab, Inc., Spring House, PA, USA. Ortho Pharmaceutical Corporation, Raritan, New Jersey, USA. December 1996.
30. Wasserstein AG, Rak I, Reife RA. Nephrolithiasis during treatment with topiramate (abstract). Epilepsia 1995; 35 (suppl 3): S153.
31. Markind JE. Topiramate: a new antiepileptic drug. Am J Health-Syst Pharm 1998; 55: 554-562.
32. Petty F, Kramer GL, Fulton M, Moeller FG, Rush AJ. Low plasma GABA is a trait-like marker for bipolar illness. Neuropsychopharmacology 1993; 9: 125-132.
33. Kuzneicky R, Hetherington H, Ho S, Pan J, Martin R, Gilliam F, Hugg J, Faught E. Topiramate increases cerebral GABA in healthy humans. Neurology 1998; 51: 627-629.
34. Hayes SG. Acetazolamide in bipolar affective disorders. Ann Clin Psychiatr 1994; 6: 91-98.
35. Brandt C, Grunze H, Norman C, Walden J. Acetazolamide in the treatment of acute mania. Neuropsychology 1998; 38: 202-203.